Monisha

[Monisha @msPublicHealth1]

@elaineleung NICE doesn't recommend interventions that are not found cost-effective in modeling analyses. Very different from the US #BlueJC

[Monisha @msPublicHealth1]

@elaineleung ACIP uses clinical rsrch 4 vaccin & screen guidelines,unlike NICE in Eurpe, they considr math modeling low level evidnc #BlueJC

[Monisha @msPublicHealth1]

@BlueJCHost #blueJC Using costs and epi data from the country or from policy makers makes modeling results more believable. Less black box

[Monisha @msPublicHealth1]

@BlueJCHost #blueJC Also helps to have in person meetings and engage policy makers at all stages of the process.

[Monisha @msPublicHealth1]

@BlueJCHost #blueJC working on cost-effective analyses commissioned by local ministries of health have been successful in informing policy

[Monisha @msPublicHealth1]

@BlueJCHost @nxpathak especially hard to mention "costs" in the US healthcare setting #blueJC

[Monisha @msPublicHealth1]

@BlueJCHost @nxpathak #blueJC engaging policymkrs has workd bettr in Europe & developing countries. More difficult w political climate in US

[Monisha @msPublicHealth1]

@BlueJCHost Q6: Clearly communicating methods and results makes research easy to understand for policy makers. Esp true for modeling.

[Monisha @msPublicHealth1]

@BlueJCHost Q6: It's important to engage policy makers early in the research process to find out which questions are most relevant to them.